MASCC／ESMO 2016 共识建议：中度致吐化疗恶心呕吐治疗.pdfVIP

Support Care Cancer DOI 10.1007/s00520-016-3365-1 SPECIAL ARTICLE 2016 updated MASCC/ESMO consensus recommendations: Prevention of nausea and vomiting following moderately emetogenic chemotherapy Fausto Roila 1 David Warr 2 Paul J. Hesketh3 Richard Gralla 4 Jorn Herrstedt 5 Karin Jordan 6 Matti Aapro 7 Enzo Ballatori 8 Bernardo Rapoport 9 Received: 6 May 2016 /Accepted: 21 July 2016 # Springer-Verlag Berlin Heidelberg 2016 Abstract Conclusions In carboplatin-treated patients, a moderate Purpose An update of the recommendations for the prophy- benefit from adding an NK1 receptor antagonist to dexa- laxis of acute and delayed emesis induced by moderately methasone and a 5-HT3 receptor antagonist has been emetogenic chemotherapy published after the last MASCC/ shown. However, in oxaliplatin-treated patients, contrast- ESMO antiemetic consensus conference in 2009 has been ing results about the role of NK1 receptor antagonists carried out. have been obtained. At present, it is not possible to sug- Methods A systematic literature search using PubMed from gest a specific 5-HT3 receptor antagonist to use for the January 1, 2009 to January 6, 2015 with a restriction to papers prevention of acute emesis in these patients. No routine in English was conducted. prophylaxis for delayed emesis is recommended but in Results Overall, two randomized phase II and seven random- patients receiving moderately emetogenic chemotherapy ized phase III studies plus the results of three subgroup anal- with known potential for delayed emesis (e.g., oxaliplatin, ysis of large phase